MAX-40279
- Generic Name
- MAX-40279
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23FN6OS
- CAS Number
- 2070931-57-4
- Unique Ingredient Identifier
- DL772G3NN7
- Background
MAX-40279 is under investigation in clinical trial NCT03412292 (MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05395780
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jingsu, China
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03412292
- Locations
- 🇦🇺
Monash Health, Clayton, Victoria, Australia
🇦🇺Western NSW Local Health District, Dubbo, New South Wales, Australia
🇦🇺St Vincent's Hospital Sydney Limited, Darlinghurst, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath